First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

NCT06840782 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

124

Enrollment

OTHER

Sponsor class

Conditions

Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Interventions

RADIATION: Radical local treatment
DRUG: SoC-based immunotherapy (+/- chemotherapy)

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris